Sliding‑Scale Insulin Is Ineffective and Should Not Be Used as Monotherapy

Sliding‑scale insulin (SSI) as the sole regimen is explicitly condemned by the American Diabetes Association and all major diabetes guideline societies; it must be replaced immediately with a scheduled basal‑bolus insulin regimen that includes basal insulin, prandial insulin, and correction doses as an adjunct. 1, 2

Why Sliding‑Scale Insulin Fails

SSI treats hyperglycemia reactively after it occurs rather than preventing it, leading to wide glucose fluctuations that worsen both hyper‑ and hypoglycemia. 1
Only ≈38 % of patients achieve mean glucose < 140 mg/dL with SSI alone, versus ≈68 % when a scheduled basal‑bolus regimen is used. 1, 2
SSI provides no basal insulin to suppress hepatic glucose production between meals and overnight, resulting in persistent fasting hyperglycemia. 1
SSI lacks scheduled prandial insulin, causing post‑prandial spikes that are later corrected with large reactive doses, creating a cycle of hyperglycemia → large correction → hypoglycemia → rebound hyperglycemia. 1
In hospitalized patients, SSI regimens are often never adjusted throughout the stay, even when glucose remains poorly controlled. 1
Studies show that SSI is associated with poor glycemic control, deficiencies in monitoring and documentation, and subtherapeutic insulin effects in 84 % of administered doses. 3
SSI has been in use for over 80 years without evidence to support its use as standard of care. 4

The Correct Approach: Scheduled Basal‑Bolus Insulin with Correction Doses

Components of a Proper Regimen

All insulin‑requiring patients need a scheduled regimen comprising three components:

Basal insulin (long‑acting: glargine, detemir, or degludec) given once daily provides continuous background coverage and suppresses hepatic glucose production. 1, 2
Prandial insulin (rapid‑acting: lispro, aspart, or glulisine) administered 0–15 minutes before each meal covers meal‑related glucose excursions. 1, 2, 5
Correction insulin is used only as a supplement to scheduled doses when pre‑meal glucose exceeds predefined thresholds; it is not a replacement for scheduled insulin. 1, 2, 5

Initial Dosing for Basal‑Bolus Therapy

Standard‑Risk Patients

Start with a total daily dose of 0.3–0.5 U/kg/day, allocating 50 % to basal insulin (once daily) and 50 % to prandial insulin (divided among three meals). 2

High‑Risk Patients (Age > 65, Renal Impairment, Poor Intake)

Use a lower starting dose of 0.1–0.25 U/kg/day to minimize hypoglycemia risk. 2

Simplified Correction‑Dose Protocol (Adjunct to Scheduled Insulin)

Correction doses must always supplement—not replace—scheduled basal and prandial insulin. 1, 2, 5

Add 2 units of rapid‑acting insulin for pre‑meal glucose > 250 mg/dL. 1, 2, 6, 5
Add 4 units for pre‑meal glucose > 350 mg/dL. 1, 2, 6, 5

Alternative individualized approach:

Calculate Insulin Sensitivity Factor (ISF) = 1500 ÷ total daily insulin dose. 2
Correction dose = (Current glucose – Target glucose) ÷ ISF. 2

Titration Protocols

Basal Insulin

Increase by 2 U every 3 days if fasting glucose is 140–179 mg/dL. 1, 2
Increase by 4 U every 3 days if fasting glucose is ≥ 180 mg/dL. 1, 2
Target fasting glucose: 80–130 mg/dL. 1, 2

Prandial Insulin

Increase each meal dose by 1–2 U (≈10–15 %) every 3 days based on 2‑hour post‑prandial glucose. 1, 2, 5
Target post‑prandial glucose: < 180 mg/dL. 1, 2, 5

Monitoring Requirements

Patients eating regular meals: check glucose before each meal and at bedtime (minimum 4 times daily). 1, 2
Patients with poor intake or NPO: check glucose every 4–6 hours. 1, 2
Daily fasting glucose is essential during titration to guide basal‑insulin adjustments. 1, 2
2‑hour post‑prandial glucose after each meal to assess prandial adequacy. 1, 2, 5

Critical Safety Warnings

Never use rapid‑acting insulin at bedtime as a sole correction dose, as this markedly increases the risk of nocturnal hypoglycemia. 1, 2, 6, 5
Never rely on SSI as monotherapy; major diabetes guidelines condemn this reactive approach. 1, 2, 4
Treat any glucose < 70 mg/dL immediately with 15 g of fast‑acting carbohydrate, recheck in 15 minutes, and repeat if needed. 1, 2
If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20 % before the next administration. 1, 2

Expected Clinical Outcomes

With properly implemented basal‑bolus therapy, ≈68 % of patients achieve mean glucose < 140 mg/dL, versus ≈38 % with SSI alone. 1, 2
Basal‑bolus therapy does not increase hypoglycemia incidence when correctly applied versus SSI monotherapy. 1, 2
For non‑critically ill hospitalized patients, the target glucose range is 140–180 mg/dL. 1, 2

Common Pitfalls to Avoid

Do not continue SSI as monotherapy when glucose repeatedly exceeds 180 mg/dL; it is inferior and unsafe. 1, 2, 4
Do not delay adding prandial insulin when basal insulin alone fails to achieve target fasting glucose. 1, 2
Do not increase basal insulin beyond 0.5–1.0 U/kg/day without addressing post‑prandial hyperglycemia, to prevent over‑basalization and hypoglycemia. 1, 2
Do not rely solely on correction doses without adjusting scheduled basal and prandial insulin. 1, 2
Studies show that uncertainties or missing information related to execution, timing, blood glucose levels, or insulin dose are present in approximately 30 % of all anticipated points of care involving SSI, highlighting the need for a structured basal‑bolus approach. 3
Sliding‑scale insulin regimens are never adjusted in 81 % of patients throughout their hospital stay, perpetuating inadequate management. 3

Special Populations

Older Adults or Frail Patients

Use a simplified approach with more conservative targets, such as premeal glucose 90–150 mg/dL. 6, 5
Consider discontinuing sliding scale when not needed daily. 6, 5
Adjust insulin doses every 2 weeks based on fingerstick glucose testing performed before lunch and before dinner. 6

Hospitalized Patients with Limited Oral Intake

Use a basal‑only or basal‑plus‑correction regimen; basal insulin must never be completely withheld because it suppresses hepatic glucose production independent of food intake. 1, 2

Timing of Blood Glucose Measurement and Insulin Administration

Blood glucose measurement and insulin dose administration should be accomplished immediately prior to mealtime to optimize glycemic control. 7
Timing of blood glucose measurement does affect the required SSI dose, reinforcing the need for proper timing in any correction‑dose protocol. 7

Evidence‑Based Alternatives to SSI

Computer order entry systems with evidence‑based minimal intervention orders (supplemental insulin only when fasting glucose exceeds 400 mg/dL) have been shown to significantly reduce the use of traditional SSI regimens from 97.1 % to 63.8 % (P < 0.001). 8
A simple, evidence‑based quick‑order in a computer order entry system can rapidly and significantly reduce use of SSI regimens for glycemic control of inpatients. 8

What is the recommended regular insulin sliding‑scale dosing protocol for hospitalized adults, including weight‑based adjustments and modifications for elderly patients or those with renal impairment?

Help us tailor your experience